Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using plac
Provided herein are placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, combined natural killer cells from placenta and umbilical cord blood, and combinations thereof. Also provided herein are compositions comprising the same, and methods of using placental perfusate, placental perfusate cells, placenta-derived intermediate natural killer cells, and combined natural killer cells and combinations thereof, to suppress the growth or proliferation of tumor cells, cancer cells, and the like, and to treat individuals having tumor cells. Also provided herein are methods of treating an individual having a tumor or graft-versus-host disease with placental perfusate, placental perfusate-derived cells, natural killer cells from placenta, e.g., from placental perfusate, and/or combined natural killer cells comprising natural killer cells from placenta, e.g., from placental perfusate, and umbilical cord blood.
대표청구항▼
1. A method of treating or preventing graft-versus-host disease, comprising administering natural killer cells isolated from human placental perfusate and umbilical cord blood to a patient with or at risk of developing graft-versus-host disease, wherein said patient has received a solid organ transp
1. A method of treating or preventing graft-versus-host disease, comprising administering natural killer cells isolated from human placental perfusate and umbilical cord blood to a patient with or at risk of developing graft-versus-host disease, wherein said patient has received a solid organ transplant or a composite tissue allograft. 2. The method of claim 1, wherein said human placental perfusate and umbilical cord blood has been treated to remove a plurality of erythrocytes. 3. The method of claim 1, wherein said natural killer cells comprise at least about 50% CD56+ cells. 4. The method of claim 1, wherein said natural killer cells comprise at least about 50% CD56+CD16− cells. 5. The method of claim 1, wherein said natural killer cells are contacted with an immunomodulatory compound in an amount and for a time sufficient for said cells to express detectably more granzyme B than an equivalent number of cells not contacted with said immunomodulatory compound. 6. The method of claim 5, wherein said immunomodulatory compound is lenalidomide or pomalidomide. 7. The method of claim 1, wherein said natural killer cells comprise: a detectably higher number of CD3−CD56+CD16− natural killer cells than an equivalent number of natural killer cells from peripheral blood;a detectably lower number of CD3−CD56+CD16+ natural killer cells than an equivalent number of natural killer cells from peripheral blood;a detectably higher number of CD3−CD56+KIR2DL2/L3+ natural killer cells than an equivalent number of natural killer cells from peripheral blood;a detectably lower number of CD3−CD56+NKp46+ natural killer cells than an equivalent number of natural killer cells from peripheral blood;a detectably higher number of CD3−CD56+NKp30+ natural killer cells than an equivalent number of natural killer cells from peripheral blood;a detectably higher number of CD3−CD56+2B4+ natural killer cells than an equivalent number of natural killer cells from peripheral blood; ora detectably higher number of CD3−CD56+CD94+ natural killer cells than an equivalent number of natural killer cells from peripheral blood. 8. The method of claim 1, wherein said natural killer cells have not been cultured. 9. The method of claim 1, wherein said natural killer cells have been cultured. 10. The method of claim 9, wherein said natural killer cells have been cultured for about 21 days. 11. The method of claim 9, wherein said natural killer cells have been cultured in the presence of feeder cells. 12. The method of claim 11, wherein additional feeder cells are added to the culture at about day 7. 13. The method of claim 1, wherein said patient has received a solid organ transplant. 14. The method of claim 1, wherein said patient has received a composite tissue allograft. 15. The method of claim 1, wherein said graft-versus-host disease is reduced in grade by at least one step by said administering. 16. The method of claim 1, wherein said graft-versus-host disease does not progress beyond grade II within 100 days after transplantation as a result of said administering. 17. The method of claim 1, wherein said graft-versus-host disease does not progress beyond grade I within 100 days after transplantation as a result of said administering. 18. The method of claim 1, wherein said natural killer cells express one or both of miRNAs hsa-miR-422a and hsa-miR-549. 19. The method of claim 1, wherein the natural killer cells express one or more of miRNAs hsa-miR-125b, hsa-miR-198, hsa-miR-450, hsa-miR-519c, hsa-miR-520c, hsa-miR-522, hsa-miR-524, and hsa-miR-627 at a detectably greater amount than an equivalent number of natural killer cells from peripheral blood. 20. The method of claim 9, wherein the natural killer cells express one or more of miRNAs hsa-miR-450, hsa-miR-520c, hsa-miR-524, and hsa-miR-627 at a detectably greater amount than an equivalent number of natural killer cells from peripheral blood.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (179)
Pittenger Mark F., Adipogenic differentiation of human mesenchymal stem cells.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Kuypers Franciscus A. ; Cole Robert B. ; Meyst Richard P. ; Gorton Lanny A. ; Wright James I., Apparatus and method for collecting blood from an umbilical cord.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Capecchi Mario R. (Salt Lake City UT) Thomas Kirk R. (Salt Lake City UT), Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and.
Heidaran, Mohammad; Wang, Jia-Lun; Ye, Qian; Zeitlin, Andrew; Dulaney, Colleen Suzanne, Co-culture of placental stem cells and stem cells from a second source.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Compositions containing cultured mitotic human stem cells.
Caplan Arnold I. ; Haynesworth Stephen E. ; Gerson Stanton L. ; Lazarus Hillard M., Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells.
Bauer S. Christopher ; Abrams Mark Allen ; Braford-Goldberg Sarah Ruth ; Caparon Maire Helena ; Easton Alan Michael ; Klein Barbara Kure ; McKearn John Patrick ; Olins Peter O. ; Paik Kumnan ; Thomas, Ex-vivo expansion of stem cells using combinations of interleukin-3 (IL-3) variants and other cytokines.
Bjornson Christopher R. ; Rietze Rod L.,AUX ; Reynolds Brent A.,CAX ; Vescovi Angelo L.,ITX, Generation of hematopoietic cells from multipotent neural stem cells.
Nakahata Tatsutoshi (Matsumoto JPX) Kawano Genji (Kamakura JPX) Sudo Tetsuo (Kamakura JPX) Kojima Katsuaki (Yokohama JPX), Hematopoietic stem cell growth-promoting compositions containing a fibroblast-derived fragment of fibronectin and a grow.
Rubinstein Pablo ; Coelho Philip Henry ; Stevens Cladd E., High concentration white cells, a method for agglomeration of the high concentration and a bag set for use in conjuncti.
Janice M. Davis-Sproul ; Mark Aaron Moorman ; Renee Marie McNeil ; Donald William Simonetti, Jr. ; Lora Catherine Hammill ; Stewart Craig, Human mesenchymal stem cells.
Srour Edward (Indianapolis IN) Zanjani Esmail (Reno NV) Brandt John E. (Indianapolis IN) Hoffman Ronald (Indianapolis IN), Human stem cell compositions and methods.
Tsukamoto Ann (Palo Alto CA) Baum Charles M. (Mountain View CA) Aihara Yukoh (Yokohama JPX) Weissman Irving (Palo Alto CA), Identification and isolation of human hematopoietic stem cells.
Johnson R. Paul (Lexington MA) Rosenzweig Michael (Boston MA) Scadden David T. (Weston MA), In vitro differentiation of CD34+progenitor cells into T lymphocytes.
Prockop Darwin J. ; Pereira Ruth F. ; Leeper Dennis B. ; O'Hara Michael D., Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects.
Edward A. Boyse ; Hal E. Broxmeyer ; Gordon W. Douglas, Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood.
Boyse Edward A. (Tucson AZ) Broxmeyer Hal E. (Indianapolis IN) Douglas Gordon W. (New York NY), Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of the.
Pykett, Mark J.; Rosenzweig, Michael; Scadden, David T.; Poznansky, Mark C., Lymphoid tissue-specific cell production from hematopoietic progenitor cells in three-dimensional devices.
Kevin R. McIntosh ; Joseph D. Mosca ; Elena N. Klyushnenkova, Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
McIntosh Kevin R. ; Mosca Joseph D. ; Klyushnenkova Elena N., Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
McIntosh, Kevin R.; Mosca, Joseph D.; Klyushnenkova, Elena, Mesenchymal stem cells for prevention and treatment of immune responses in transplantation.
McGlave Philip B. (St. Paul MN) Verfaillie Catherine M. (St. Paul MN) Miller Jeffrey S. (Little Canada MN), Method for culturing human hematopoietic stem cells in vitro.
Caplan Arnold I. (1300 Oakridge Dr. Cleveland Heights OH 44121) Haynesworth Stephen E. (3643 Antisdale Rd. Cleveland Heights OH 44118), Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Method for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultur.
Caplan Arnold I. (1300 Oakridge Dr. Cleveland Heights OH 44121) Haynesworth Stephen E. (3643 Antisdale Rd. Cleveland Heights OH 44118), Method for treating connective tissue disorders.
Murray Lesley (San Jose CA) Sutherland D. Robert (Oakville CAX), Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby an.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI) Schwartz Richard M. (Ann Arbor MI), Methods and compositions for the ex vivo replication of human hematopoietic stem cells.
Emerson Stephen G. ; Clarke Michael F. ; Palsson Bernhard O., Methods and compositions for the ex vivo replication of stem cells, for the optimization of hematopoietic progenitor cell cultures, and for increasing the metabolism, GM-CSF secretion and/or IL-6 sec.
Fei Rui G. (Seattle WA) Heimfeld Shelly (Woodinville WA) Minshall Billy W. (Mill Creek WA) Berenson Ronald J. (Mercer Island WA), Methods and device for culturing human hematopoietic cells and their precursors.
Anderson David J. ; Shah Nirao M., Methods for differentiating neural stem cells to neurons or smooth muscle cells using TGT-.beta. super family growth factors.
Csete Marie ; Doyle John ; Wold Barbara, Methods for isolation and activation of, and control of differentiation from, skeletal muscle stem or progenitor cells.
Palsson Bernhard O. (Ann Arbor MI) Armstrong R. Douglas (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Emerson Stephen G. (Ann Arbor MI), Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Methods for the ex vivo replication of human stem cells and/or expansion of human progenitor cells.
Hill Beth Louise ; Rozler Elen ; Chen Benjamin P., Methods of obtaining compositions enriched for hematopoietic stem cells, antibodies for use therein, compositions derived therefrom and methods of use thereof.
Emerson Stephen G. (Ann Arbor MI) Clarke Michael F. (Ann Arbor MI) Palsson Bernhard O. (Ann Arbor MI), Methods, compositions and devices for growing human hematopoietic cells.
Palsson Bernhard O. ; Emerson Stephen G. ; Schwartz Richard M., Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells.
Hariri,Robert J.; Stirling,David I.; Moutouh De Parseval,Laure A.; Chan,Kyle W. H., Modulation of stem and progenitor cell differentiation, assays, and uses thereof.
Vyakarnam Murty N. ; Zimmerman Mark C. ; Scopelianos Angelo George ; Roller Mark B. ; Gorky David V., Porous tissue scaffoldings for the repair of regeneration of tissue.
Vyakarnam, Murty N.; Zimmerman, Mark C.; Scopelianos, Angelo George; Roller, Mark B.; Gorky, David V., Porous tissue scaffoldings for the repair or regeneration of tissue.
Boyse Edward A. (New York NY) Broxmeyer Hal E. (Indianapolis IN) Douglas Gordon W. (New York NY), Preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood.
Stern David M. (Great Neck NY) Oz Mehmet C. (Fort Lee NJ) Nowygrod Roman (Teaneck NJ) Koga Shin (New York NY) Pinsky David J. (Riverdale NY), Solution for prolonged organ preservation.
McIntosh, Kevin; Klyushnenkova, Elena, Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation.
Gerson Stanton L. (Pepper Pike OH) Caplan Arnold I. (Cleveland Heights OH) Haynesworth Stephen E. (Cleveland Heights OH), Transduced mesenchymal stem cells.
Hessel Stephen R. (Fountain Valley CA) Young H. Theodore (Lake Forest CA) Katz Michael (Richmond CA), Umbilical cord clamping, cutting, and blood collecting device and method.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.